Proscia Receives FDA 510(k) Clearance For Concentriq AP-Dx

Key regulatory milestone advances company's mission to perfect cancer diagnosis PHILADELPHIA, Feb. 12, 2024 /PRNewswire-PRWeb/ -- Proscia®, a leading provider of digital and computational pathology solutions, has received 510(k) clearance from the United States (U.S.) Food and Drug...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Tags: FDA Source Type: news